![](/img/cover-not-exists.png)
P-157A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)
Iwamoto, S., Hazama, S., Kin, H., Takemoto, H., Kobayashi, K., Takahashi, Y., Kobayashi, M., Maeda, H., Nagata, N., Oba, K., Sakamoto, J., Mishima, H.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw199.151
Date:
June, 2016
File:
PDF, 65 KB
english, 2016